An Open-label, Multiple-dosing, Two-arms, One-sequence Study to Evaluate the Safety and Pharmacokinetics After Co-administration of Exforge (Amlodipine Besylate/Valsartan) and Lipitor (Atorvastatin Ca) in Healthy Male Volunteers

Trial Profile

An Open-label, Multiple-dosing, Two-arms, One-sequence Study to Evaluate the Safety and Pharmacokinetics After Co-administration of Exforge (Amlodipine Besylate/Valsartan) and Lipitor (Atorvastatin Ca) in Healthy Male Volunteers

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Amlodipine/valsartan (Primary) ; Atorvastatin (Primary)
  • Indications Cardiovascular disorders; Diabetic nephropathies; Dyslipidaemias; Hypertension
  • Focus Pharmacokinetics
  • Sponsors CJ Cheiljedang Corp.
  • Most Recent Events

    • 03 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top